[1]陈紫薇,陈 明△.从脾论治慢性肾脏病的生物学基础探讨*[J].陕西中医,2020,(11):1627-1631.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
　CHEN Ziwei,CHEN Ming..Discuss the biological foundation for chronic disease therapy from treatment through the spleen[J].,2020,(11):1627-1631.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
点击复制

从脾论治慢性肾脏病的生物学基础探讨*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2020年11期
页码:
1627-1631
栏目:
学术探讨
出版日期:
2020-11-05

文章信息/Info

Title:
Discuss the biological foundation for chronic disease therapy from treatment through the spleen
作者:
陈紫薇1; 陈 明2△
1.成都市中西医结合医院肾内科(成都 610041); 2.成都中医药大学附属医院(成都 610072)
Author(s):
CHEN Ziwei; CHEN Ming.
The Department of Nephrology from Chengdu Integrated TCM and Western Medicine Hospital(Chengdu 610041)
关键词:
慢性肾脏病;  从脾论治;  肠道菌群;  生物学基础
Keywords:
Chronic kidney disease;  Treatment through the spleen;  Gut microbiota;  Biological foundation
分类号:
R692
DOI:
DOI:10.3969/j.issn.1000-7369.2020.11.029
文献标志码:
A
摘要:
脾为后天之源,肾为先天之本,以后天滋先天,使从脾论治成为中医临床治疗慢性肾脏病(CKD)的经典方法。现代医学研究发现人体内最庞大的“器官”——肠道菌群与“脾”的功能非常密切。目前研究发现肠道菌群紊乱是加速CKD进展的重要环节,基于脾肾互根互用的中医原理,收集、整理肠道菌群与CKD代谢功能、免疫应答及肾脏损伤关联的文献,从肠道菌群与机体功能代谢和内环境稳态的角度进行探讨,认识到运用中医药可通过干预肠道菌群的丰度、结构和代谢功能,维持肠道微生态的平衡,从而达到调节肾脏代谢和免疫应答的作用,提出肠道菌群是从脾论治慢性肾脏病的重要生物学基础。
Abstract:
According to Chinese medicine theory the spleen is regarded as the root of after-birth and the kidney as the origin of the body.The treatment through the spleen has become a classic method in the clinical experience of chronic kidney disease(CKD)because the root of after-birth can nourish the origin.Modern research has found that the gut microbiota is the largest “organ” in the human body,which is closely related to the spleen at the same time.Current studies have found that there are some links between gut microbiota disorder and process of CKD acceleration.Based on the TCM principle of spleen and kidney mutual interaction,we are collecting and organizing the literature about gut microbiota,CKD metabolism function and immune response.After that we have realized that in the perspective of gut microbiota,body function metabolism and internal environment homeostasis,the Chinese medicine intervention could maintain the balance of gut microbiota through regulate the abundance,structure and metabolic function,then adjust the metabolism and immune response of kidney.It is suggested that gut microbiota is an important biological basis for the treatment of chronic kidney diseases from the spleen.

参考文献/References:

[1] Bikbov B,Purcell CA,Levey AS,et al.Global,regional,and national burden of chronic kidney disease,1990-2017:a systematic analysis for the global burden of disease study 2017[J].The Lancet,2020,395(10225):709-733.
[2] 陈继红,盛梅笑,许陵冬,等.基于真实世界原理评价益肾清利泄浊方治疗慢性肾脏病3期患者临床疗效的研究[J].世界科学技术-中医药现代化,2019,21(6):1055-1061.
[3] 桂志红,黄 刚,王华富,等.加昧益肾活血方对慢性肾脏病5期患者肠道微生态的影响[J].南京中医药大学学报,2019,35(3):258-261.
[4] 封 慧,朱欣轶,王长松.健脾中药对肠道微生态作用机制研究进展[J].中国中医药信息杂志,2018,25(10):137-140.
[5] 赵 静,陈继红,严 谨,等.慢性肾脏病中医证候类型及治则专家问卷调查结果分析[J].世界科学技术-中医药现代化,2019,21(6):1068-1074.
[6] 陈耿超.慢性肾脏病5期非透析患者的中医证候调查研究[D].广州:广州中医药大学,2013.
[7] 赖玮婧,刘 芳,付 平.慢性肾脏病评估及管理临床实践指南解读——从K/DOQI到KDIGO[J].中国实用内科杂志,2013,33(6):448-453.
[8] 赵 华,刘 溪.香砂六君子对老年慢性肾脏病患者血清肌酐、瘦素及IL-6水平的影响研究[J].中国生化药物杂志,2016,36(5):127-129.
[9] 李颖群.六君子汤合六味地黄加减结合西医治疗糖尿病肾病58例的疗效观察[J].中国医药指南,2012,10(4):244-245.
[10] 汪 力,王少清,李 曦,等.肾康注射液联合结肠透析治疗慢性肾脏病118例[J].陕西医学杂志,2014,43(12):1675-1676,1684.
[11] Meijers BK,Evenepoel P.The gut-kidney axis:indoxyl sulfate,p-cresyl sulfate and CKD progression[J].Nephrol Dial Transplant,2011,26(3):759-761.
[12] Pahl MV,Vaziri ND.The chronic kidney disease - colonic axis[J].Semin Dial,2015,28(5):459-463.
[13] Yang CY,Tarng DC.Diet,gut microbiome and indoxyl sulphate in chronic kidney disease patients[J].Nephrology(Carlton),2018(23):16-20.
[14] Chung S,Barnes JL,Astroth KS.Gastrointestinal microbiota in patients with chronic kidney disease:a systematic review[J].Adv Nutr,2019,10(5):888-901.
[15] Wong J,Piceno YM,Desantis TZ,et al.Expansion of urease- and uricase-containing,indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD[J].Am J Nephrol,2014,39(3):230-237.
[16] Chen H,Chen L,Liu D,et al.Combined clinical phenotype and lipidomic analysis reveals the impact of chronic kidney disease on lipid metabolism[J].J Proteome Res,2017,16(4):1566-1578.
[17] Li DY,Tang W.Contributory role of gut microbiota and their metabolites toward cardiovascular complications in chronic kidney disease[J].Semin Nephrol,2018,38(2):193-205.
[18] Mafune A,Iwamoto T,Tsutsumi Y,et al.Associations among serum trimethylamine-N-oxide(TMAO)levels,kidney function and infarcted coronary artery number in patients undergoing cardiovascular surgery:a cross-sectional study[J].Clin Exp Nephrol,2016,20(5):731-739.
[19] Shiba T,Makino I,Kawakami K,et al.p-Cresyl sulfate suppresses lipopolysaccharide-induced anti-bacterial immune responses in murine macrophages in vitro[J].Toxicol Lett,2016(245):24-30.
[20] Brandsma E,Kloosterhuis NJ,Koster M,et al.A Proinflammatory gut microbiota increases systemic inflammation and accelerates atherosclerosis[J].Circ Res,2019,124(1):94-100.
[21] Garcia AF,Gonzaga G,Munoz JI,et al.Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage[J].PLoS One,2018,13(8):202901.
[22] Rossi M,Johnson DW,Morrison M,et al.Synbiotics easing renal failure by improving gut microbiology(SYNERGY):a randomized trial[J].Clin J Am Soc Nephrol,2016,11(2):223-231.
[23] Wang IK,Wu YY,Yang YF,et al.The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients:a randomised,double-blind,placebo-controlled trial[J].Benef Microbes,2015,6(4):423-430.
[24] Asai M,Kumakura S,Kikuchi M.Review of the efficacy of AST-120 on renal function in chronic kidney disease patients[J].Ren Fail,2019,41(1):47-56.
[25] Noel S,Martina LM,Bandapalle S,et al.Intestinal microbiota-kidney cross talk in acute kidney injury and chronic kidney disease[J].Nephron Clin Pract,2014,127(1-4):139-143.
[26] 杨轶仑,路晓光.肠道菌群与肠黏膜机械屏障关系研究进展[J].内蒙古医学杂志,2019,51(10):1195-1197.
[27] 俞昊男,刘志华.肠道微生物与黏膜免疫研究的前沿进展[J].中国免疫学杂志,2019,35(16):1921-1930.
[28] 司原成.健脾益气针法对肥胖鼠肠道菌群及肠黏膜TLRs/TRAF6信号通路的调控研究[D].成都:成都中医药大学,2017.
[29] 姜 华,杨景明.参苓白术散对脾虚小鼠肠道功能的影响及其机制研究[J].亚太传统医药,2016,12(7):16-17.
[30] 陈 硕,牛天慧,孟凡荣,等.脾虚痰湿证代谢综合征患者肠道菌群的定量研究及其意义[J].解放军医药杂志,2018,30(3):9-12.
[31] 尹 朋,赵 烨,朱晓宇,等.实验性脾虚大鼠小肠结构与免疫功能的变化[J].中国兽医杂志,2010,46(12):16-19.
[32] 陈 琛,江振友,宋克玉,等.中草药对小鼠肠道菌群影响的实验研究[J].中国微生态学杂志,2011,23(1):15-17.
[33] 于 莲,徐 新,张 磊,等.PCR-DGGE法测定纳米山药多糖靶向制剂对大鼠肠道菌群失调的调整作用[J].中国微生态学杂志,2016,28(11):1269-1272.
[34] 祝丽超,毕 夏,陈晓杨.真人养脏汤合参苓白术散加减对虚寒型泄泻患者免疫功能及肠道微生态的影响[J].现代中西医结合杂志,2018,27(31):3451-3454.
[35] 陈玲玲,张思为,李董平,等.薏苡附子败酱散对糖尿病小鼠炎症因子及肠道菌群的影响[J].陕西中医,2018,39(4):415-418.
[36] 罗学文.健脾益肾泄浊法对慢性肾脏病5期代谢毒素和肠道菌群的影响[D].广州:广州中医药大学,2015.
[37] 杨桂莲.自拟补气活血泄浊汤对慢性肾衰竭非透析患者(脾肾两虚)硫酸对甲酚、硫酸吲哚酚的影响临床研究[D].成都:成都中医药大学,2017.
[38] 钟 丹,黄宇清,许秀珍,等.健脾补肾活血泄浊法对慢性肾衰患者肠道屏障功能的影响[J].井冈山大学学报,2018,39(2):74-77.
[39] 桂志红,黄 刚,王华富,等.加昧益肾活血方对慢性肾脏病5期患者肠道微生态的影响[J].南京中医药大学学报,2019,35(3):258-261.

相似文献/References:

[1]屈 凯,王悦彤,王漱非,等.基于文献研究探讨益肾散结法防治肾小球硬化的理论内涵*[J].陕西中医,2019,(7):919.
　QU Kai,WANG Yuetong,WANG Shufei,et al.Based on literature research to explore the theoretical connotation of Kidney-reinforcing and Mass-disintegrating for prevention and treatment of glomerulosclerosis[J].,2019,(11):919.
[2]任永朋,华 琼,刘彦妍,等.中医“治未病”思想在防治肾脏病中的应用*[J].陕西中医,2019,(8):1101.
　REN Yongpeng,HUA Qiong,LIU Yanyan,et al.The application of the thought of “preventive treatment of disease” in the prevention and treatment of kidney disease in traditional Chinese medicine[J].,2019,(11):1101.
[3]张宏强,李桂霞,章彩凤,等.许筠治疗慢性肾病临床药对举隅*[J].陕西中医,2020,(6):808.[doi:DOI:10.3969/j.issn.10007369.2020.06.031]
[4]潘宗妃,熊莉华△.熊莉华教授从脾论治糖尿病经验*[J].陕西中医,2020,(10):1464.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.035]
　PAN Zongfei,XIONG Lihua..Experience of professor XIONG Lihua in treating diabetes mellitus based on regulating spleen[J].,2020,(11):1464.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.035]
[5]黄 进,陆雪萍.非酒精性脂肪性肝病从脾论治刍议[J].陕西中医,2021,(2):225.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.022]
　HUANG Jin,LU Xueping.Analysis of treatment of nonalcoholic fatty liver disease from spleen[J].,2021,(11):225.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.022]
[6]董 怡,马 静,余楠楠,等.大黄复方保留灌肠辅助治疗慢性肾脏病疗效及对患者生活质量的影响[J].陕西中医,2021,(7):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
　DONG Yi,MA Jing,YU Nannan,et al.Effect analysis of rhubarb compound retention enema adjuvant treatment of chronic kidney disease and its impact on patients' quality of life[J].,2021,(11):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
[7]邹小秋,黄晓华,吉训超.性早熟从脾论治探讨[J].陕西中医,2021,(7):935.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.033]
　ZOU Xiaoqiu,HUANG Xiaohua,JI Xunchao.Treatment of precocious puberty based on spleen[J].,2021,(11):935.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.033]
[8]齐 宁,宋姝西,刘香玉,等.参芪延肾方治疗慢性肾脏病疗效及对患者半乳糖缺陷IgA1、晚期糖基化终产物和微炎性反应状态的影响[J].陕西中医,2022,(5):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
　QI Ning,SONG Shuxi,LIU Xiangyu,et al.Effects of Shenqi Yanshen recipe on the levels of Gd-IgA1,AGEs and micro inflammatory response in patients with chronic kidney disease[J].,2022,(11):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
[9]麦芳雄,张香兰,朱德礼.温肾健脾清化汤辅助治疗脾肾气虚型慢性肾脏病疗效及对患者血清转化生长因子β1、纤维连接蛋白水平的影响[J].陕西中医,2022,(8):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
　MAI Fangxiong,ZHANG Xianglan,ZHU Deli.Clinical efficacy of Wenshen Jianpi Qinghua decoction in the treatment of chronic kidney disease with spleen-kidney qi deficiency and its effect on serum transforming growth factor β1 and fibronectin levels[J].,2022,(11):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
[10]杨淑彬,李 婷,李晓妮,等.不同中药结肠透析模式对慢性肾脏病患者胃肠道症状和营养状态的影响[J].陕西中医,2022,(12):1698.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.010]
　YANG Shubin,LI Ting,LI Xiaoni,et al.Effects of different colon dialysis modes of traditional Chinese medicine on gastrointestinal symptoms and nutritional status in patients with chronic kidney disease[J].,2022,(11):1698.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.010]

备注/Memo

备注/Memo:
*国家自然科学基金资助项目(81973673)
更新日期/Last Update: 2020-11-09